<DOC>
	<DOCNO>NCT00732147</DOCNO>
	<brief_summary>Diabetes affect almost 21 million people United States . In study test drug call Pramlintide ( Symlin ) , see work lower blood sugar fat level meal . Lowering high sugar level fat level meal important prevention problem person type 2 diabetes often encounter . Hypothesis Pramlintide low blood sugar fat level meal .</brief_summary>
	<brief_title>Effects Pramlintide Endogenous Production Very-low-density-lipoprotein ( VLDL ) -Triglyceride Glucose Post Prandial State T2DM</brief_title>
	<detailed_description>A well recognize troublesome feature diabetes management exacerbate post prandial glucose elevation follow typical high fat meal . To date mechanism drive increase post prandial glycemia unclear . Pramlintide believe affect intermediary metabolism well nutrient absorption . The relative contribution alter absorption metabolism observe post prandial reduction plasma glucose TG concentration remain uncertain , however . Combinations radioactive stable isotope label technique able quantify relevant flux glucose lipid vivo human therefore able provide quantitative answer question . Aims : 1 . To determine effect Pramlintide reduce endogenous production very-low-density-lipoprotein ( VLDL ) -triglycerides ( TG ) follow high fat breakfast , lunch dinner patient type 2 diabetes mellitus ( T2DM ) . A triple isotope approach use determine rate appearance ( VLDL ) -triglycerides follow breakfast , lunch dinner . 2 . To compare relative role slow glucose absorption reduce endogenous glucose production ( glucagonstatic mechanism ) glucose-lowering effect Pramlintide post prandial state patient T2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Type 2 DM study participant CPeptide positive ( level &gt; 0.3 nmol/L ) Receiving insulin , metformin and/or sulfonylurea/glitinide . Maintained stable antihypertensive medication . BMI &lt; 52 kg/m2 . T2DM least 3 month HBA1C 10 % . Receiving TZDs , exenatide , sitagliptin pramlintide therapy . Receiving medication know impair gastric emptying , intestinal motility , glucagon release corticosteroid . Triglyceride level &gt; 400 mg/dl . BMI &gt; 52 kg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>triglyceride</keyword>
	<keyword>endogenous</keyword>
	<keyword>glucose</keyword>
	<keyword>production</keyword>
</DOC>